Information checked: November 9, 2026, at 9:05 p.m. UTC.
The U.S. Food and Drug Administration announced November 9 that it is requiring a warning about a potential increased risk of a rare but serious eye condition called NAION in the prescribing information for all GLP-1 receptor agonist medicines. The requirement includes Ozempic (semaglutide) and Zepbound (tirzepatide). NAION can cause sudden, painless vision loss, sometimes permanently.
For people taking these medicines, the immediate step is to know which vision changes need prompt attention and discuss personal risks and benefits with the prescribing clinician. The FDA advises patients to contact a health care professional right away if symptoms occur. If you have sudden vision loss and cannot immediately reach a clinician or eye specialist, seek emergency care rather than waiting for a routine appointment. Read the FDA safety communication.
Destaques
The FDA is requiring manufacturers to add information about the potential increased risk of non-arteritic anterior ischemic optic neuropathy, or NAION, to the Warnings and Precautions section of their products’ labeling. This is a labeling requirement announced by the agency; an individual product’s posted label may take time to reflect the change.
Ozempic contains semaglutide, while Zepbound contains tirzepatide, which acts on both GIP and GLP-1 receptors. The FDA says NAION cases have been reported with all currently marketed GLP-1 receptor agonist products. That does not establish that every reported case was caused by a medicine, or that the risk is identical for every product or patient.
NAION involves reduced blood flow to the front of the optic nerve. Symptoms can include sudden, painless loss of vision in one eye, sometimes noticed on waking; blurred or missing areas of vision; blind spots or tunnel vision; changes in color perception; or a hazy area affecting central vision. Not every vision change is NAION, and other causes can also be urgent.
Contact your health care professional immediately if these symptoms appear. Say when the change began, whether it affects one or both eyes, and which medicines you take. The FDA advises clinicians to promptly refer patients with suspected NAION to an ophthalmologist. Do not wait to see whether a sudden change clears on its own.
In an FDA analysis combining 126 randomized trials, the rate of probable NAION was 6.4 cases per 100,000 person-years among people receiving a GLP-1 medicine, compared with 3.8 per 100,000 person-years among those receiving a placebo or a different type of glucose-lowering medicine. A person-year is one person followed for one year, so these figures are rates across the accumulated follow-up, not a precise lifetime risk or a prediction for an individual.
There were only 15 probable cases across the trials, making precise estimates difficult. The FDA also reviewed observational research and safety reports. Its own real-world analysis found different results depending on the comparison drug: no statistically significant increase versus SGLT-2 inhibitors, but an increase versus DPP-4 inhibitors. The agency concluded that there is a potential increased risk. The underlying mechanism remains unclear, and the data do not provide a reliable head-to-head risk comparison for Ozempic versus Zepbound.
If you have no new symptoms, arrange a conversation with the clinician who prescribes your medicine. Bring its name and dose, the reason you take it, a list of your other medicines, and any relevant eye records. These questions can make the discussion more useful:
Do not change or stop a prescribed medicine solely because of a headline without discussing it with your clinician. If a dose is due and you have a new sudden vision symptom, seek immediate medical advice and ask the treating clinician how to handle that dose; do not delay evaluation while trying to resolve the medication question.
No. NAION affects the optic nerve; diabetic retinopathy damages blood vessels in the retina. Both matter when discussing vision, especially for people with diabetes. The Ozempic prescribing information also warns about diabetic retinopathy complications and recommends monitoring patients with a history of diabetic retinopathy. Ask your diabetes clinician and eye doctor how your blood sugar and eye history affect your monitoring plan.
The FDA’s announcement means clinicians and patients have new safety information to consider, not a certain forecast of who will develop NAION. Keep routine care appointments, ask for an individualized plan, and report a suspected medication side effect through FDA MedWatch. Reporting does not replace urgent medical care.
No. Discuss your personal risks and benefits with your prescriber. If you have a sudden vision change, seek immediate medical attention.
Yes. The FDA says NAION can cause permanent vision loss, which is why sudden symptoms warrant prompt evaluation.
Not necessarily. The FDA requires a class-wide warning, but its communication does not establish an equal risk for the two individual medicines.
Nineteen David Jones stores are expected to close by year-end. Here’s what shoppers should know about gift cards, returns and paid online orders.
Severe storm warnings and forecast risks vary by region in Australia. Get Bureau of Meteorology updates, shelter and flood safety advice, and outage guidance.
David Jones will close 19 stores across Australia and New Zealand by year-end. See the confirmed locations, expected timeline and what remains undecided.
The Bureau of Meteorology forecasts storms across several regions on November 12, with severe weather possible in southeast Queensland and parts of New South Wales.
Fallout 5 is in preproduction on Creation Engine 3, but Bethesda has announced no release date, platforms, or PC requirements. Here’s what UK gamers should—and shouldn’t—buy now.
Fallout 5 remains in preproduction, with no release date or platforms confirmed. Here is Bethesda’s latest status update and what it means for UK players.
Bethesda says Fallout 5 is in preproduction on Creation Engine 3, with The Elder Scrolls VI its main focus. Here is what is confirmed—and what remains unknown.
An ICE charter carrying Iranian detainees reportedly returned to Mesa after Pakistan refused the group. Here’s what’s known, what remains unclear and how it differs from an earlier canceled flight.
Kyle McCord is in line for his first Dolphins start after Malik Willis went on IR. See his profile, NFL fit, Colts kickoff time and what it could mean for Miami’s 2027 draft.
Miami placed Malik Willis on injured reserve, opening the door for Kyle McCord to start against Indianapolis. Here’s what the move means for the Dolphins’ QB depth chart.
